If you or a loved one is taking Tysabri, it's natural to wonder whether new symptoms are from the medication or something more serious like progressive multifocal leukoencephalopathy (PML). This page builds on established medical knowledge about Tysabri's risks to help you distinguish between common side effects and early warning signs of PML. Here we clarify the symptoms versus diagnosis checklist so you can take informed next steps.
Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The prognosis for patients who develop PML while on Tysabri is poor, and the condition is often permanent, leading to death or severe disability. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical trial data and post-marketing surveillance. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 patients with multiple sclerosis treated for a median of 120 weeks, and both had received Tysabri in addition to interferon beta-1a. The third case occurred after eight doses in one of 1043 patients with Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The permanence of PML is a critical concern. The boxed warning emphasizes that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This indicates that even if a patient survives, the neurological damage is often irreversible, resulting in permanent deficits such as paralysis, cognitive impairment, or vision loss. The FDA's warnings and precautions section reiterates that PML "typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Therefore, for most affected patients, PML is a permanent condition with lasting consequences.
Several risk factors increase the likelihood of developing PML while on Tysabri. These include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning advises that these factors "should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This means that patients with these risk factors face a higher chance of developing PML, and the prognosis is correspondingly worse. The timeline between exposure to Tysabri and documented harm is variable. PML can occur during treatment, but it has also been reported after discontinuation. The FDA warns that "PML has been reported following discontinuation of TYSABRI in patients who did not have findings suggestive of PML at the time of discontinuation" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This highlights that the risk does not end when the drug is stopped. Patients are advised to continue monitoring for new signs or symptoms suggestive of PML for at least six months after discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This extended monitoring period underscores the potential for delayed onset of PML, which can affect prognosis by allowing the infection to progress before detection.
The adequacy of warnings regarding Tysabri and PML is a key risk consideration. The FDA has mandated a boxed warning, which is the strongest warning level, and a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program ensures that patients are informed of the risks and that healthcare providers monitor for PML. The warnings also specify that Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, the prognosis remains poor because PML is often advanced by the time symptoms appear, and there is no specific antiviral treatment for the JC virus. Prognosis-related considerations for affected patients include the need for early detection and supportive care. The FDA recommends that healthcare professionals monitor patients for any new sign or symptom that may be suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In multiple sclerosis patients, an MRI scan should be obtained before starting Tysabri to help differentiate subsequent multiple sclerosis symptoms from PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For Crohn's disease patients, a baseline brain MRI may also be helpful (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, even with early detection, the damage from PML is often permanent, and patients may require long-term rehabilitation and supportive care.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Yes, for most patients, PML from Tysabri is permanent. The FDA boxed warning states that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Survivors often have irreversible neurological deficits such as paralysis, cognitive impairment, or vision loss.
Risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors increase the likelihood of developing PML and worsen prognosis.
Yes, PML has been reported after discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Monitoring for new symptoms should continue for at least six months after discontinuation.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.